Heidelberg

• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af … Recruiting
  2025-522400-24-00 10 2026-01-27 Metastatic urothelial cancer
• A Randomized controlled open-label phase II trial assessing the efficacy and safety of two-dosing regimens of frozen encapsulated fecal micr … Recruiting
  2024-519748-34-00 4 2026-01-23 Infections with multidrug-resistant Enterobacteriaceae
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Metastatic Clear Cell Renal Cell Carcinoma
• Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma Recruiting
  2025-522090-11-00 9 2026-01-22 Relapsed or Refractory Multiple Myeloma (RRMM)
• ​​Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting
  2024-519404-27-00 5 2026-01-16 ​​IDH-mutant grade 2 or 3 astrocytoma​
• An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with S … Recruiting
  2024-520208-25-00 4 2026-01-15 Still’s disease
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 Early-Stage Parkinson’s Disease (PD)
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee ( ATTAIN-OA PAIN ) Recruiting
  2025-522631-34-00 5 2026-01-14 Osteoarthritis
• Metformin for cancer prevention in Li-Fraumeni Syndrome (LFS) Recruiting
  2025-520714-63-00 5 2026-01-05 Li-Fraumeni syndrome
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou … Recruiting
  2025-521144-38-00 4 2025-12-23 Primary Central Nervous System Lymphoma
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Recruiting
  2025-521003-52-00 9 2025-12-19 HER2 Expressing Advanced Breast Cancer
• An Open-Label Extension Study for Participants with PAH Who Have Previously Participated in a Clinical Trial with PF-07868489 Recruiting
  2025-521155-23-00 4 2025-12-19 Pulmonary Arterial Hypertension
• To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan … Recruiting
  2025-521128-31-00 9 2025-12-18 Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
• Efficacy and Safety of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity Recruiting
  2025-520831-18-00 4 2025-12-12 Primary Sjogren’s Disease
• EPIK-P4: A Phase II single-arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patien … Recruiting
  2024-519960-42-00 4 2025-12-11 PIK3CA-Related Overgrowth Spectrum (PROS)
• A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE) Recruiting
  2024-518780-36-00 3 2025-12-10 Systemic Lupus Erythematosus
• A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non … Recruiting
  2024-515125-28-00 4 2025-12-08 Non-obstructive hypertrophic cardiomyopathy
• A study to find out how EMPAgliflozin is tolerated and if it helps children and adolescents with chronic KIDNEY disease (EMPA-KIDNEY Kids) Recruiting
  2024-512577-27-00 5 2025-12-02 Chronic kidney disease in paediatric patients
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A phase 3b study of depemokimab on airway structure and function in patients with type 2 asthma utilizing quantitative high-resolution CT an … Recruiting
  2024-519976-19-00 5 2025-11-26 Asthma with type 2 inflammation characterized by an eosinophilic pheno
• Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-520927-26-00 5 2025-11-24 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• Silexan® in mild to moderate major depressive disorder Recruiting
  2025-521744-37-00 5 2025-11-17 Mild to moderate major depressive disorder
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Recruiting
  2024-517281-42-00 7 2025-11-12 Advanced solid tumors

Showing 145–168 of 732 trials